In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1125-80-0, name is 3-Methylisoquinoline, introducing its new discovery. Computed Properties of C10H9N
Imine hydrogenation catalyzed by iridium complexes comprising monodentate chiral phosphoramidites and N-donor ligands
The relatively inexpensive chiral monodentate phosphoramidite (S)-MONOPHOS may be used in combination with pyridines to prepare iridium complexes effective for catalysis of asymmetric imine hydrogenation with comparable enantioselectivity to some of those containing more costly chiral bidentate phosphines. [Ir(cod)((S)-MONOPHOS)(L)]BArF (cod = 1,5-cyclooctadiene; L = 3-methylisoquinoline, acridine, 2,6-lutidine, acetonitrile, or 2,3,3-trimethylindolenine; BArF = tetrakis[3,5-bis(trifluoromethyl)phenyl]borate) are efficient catalysts for the asymmetric hydrogenation of 2,3,3-trimethylindolenine. An important observation is that the catalyst containing acridine is more enantioselective than the catalyst derived from 2,3,3-trimethylindolenine which suggests that the other N-donor ligands are not readily displaced by the substrate during the catalytic cycle.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 1125-80-0, and how the biochemistry of the body works.Computed Properties of C10H9N
Reference：
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem